- Home
- TMDX vs MRUS Comparison
TMDX vs MRUS Comparison
Compare TMDX & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMDX
- MRUS
- Stock Information
- Founded
- TMDX 1998
- MRUS 2003
- Country
- TMDX United States
- MRUS Netherlands
- Employees
- TMDX N/A
- MRUS N/A
- Industry
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- TMDX Health Care
- MRUS Health Care
- Exchange
- TMDX Nasdaq
- MRUS Nasdaq
- Market Cap
- TMDX 2.3B
- MRUS 2.7B
- IPO Year
- TMDX 2019
- MRUS 2016
- Fundamental
- Price
- TMDX $88.24
- MRUS $43.06
- Analyst Decision
- TMDX Buy
- MRUS Strong Buy
- Analyst Count
- TMDX 10
- MRUS 13
- Target Price
- TMDX $118.44
- MRUS $86.85
- AVG Volume (30 Days)
- TMDX 1.1M
- MRUS 872.0K
- Earning Date
- TMDX 04-29-2025
- MRUS 05-07-2025
- Dividend Yield
- TMDX N/A
- MRUS N/A
- EPS Growth
- TMDX N/A
- MRUS N/A
- EPS
- TMDX 1.01
- MRUS N/A
- Revenue
- TMDX $441,540,000.00
- MRUS $36,133,000.00
- Revenue This Year
- TMDX $25.33
- MRUS $26.81
- Revenue Next Year
- TMDX $20.53
- MRUS $23.85
- P/E Ratio
- TMDX $87.37
- MRUS N/A
- Revenue Growth
- TMDX 82.74
- MRUS N/A
- 52 Week Low
- TMDX $55.00
- MRUS $33.19
- 52 Week High
- TMDX $177.37
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- TMDX 70.61
- MRUS 51.15
- Support Level
- TMDX $82.62
- MRUS $33.19
- Resistance Level
- TMDX $88.48
- MRUS $43.46
- Average True Range (ATR)
- TMDX 5.48
- MRUS 3.53
- MACD
- TMDX 1.98
- MRUS 0.34
- Stochastic Oscillator
- TMDX 99.09
- MRUS 80.53
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.